Skip Navigation

European Heart Journal 2004 25(7):537-539; doi:10.1016/j.ehj.2003.11.005
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sato, M
Right arrow Articles by Poole-Wilson, P.A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sato, M
Right arrow Articles by Poole-Wilson, P.A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

ß-blockers, myocardial ischaemia and collateral circulation

M Sato*, S.E Harding and P.A Poole-Wilson

Department of Cardiac Medicine, National Heart and Lung Institute, Imperial College Faculty of Medicine, London, UK

* Corresponding author: Dr M. Sato, Imperial College London, London, UK
E-mail address: m.sato@imperial.ac.uk

The first 10% of the full text of this article appears below.

This editorial refers to "Heart rate reduction during exercise-induced myocardial ischemia and stunning" by X. Monnet et al. on page 579, and "Coronary collateral perfusion in patients with coronary artery disease: effect of metoprolol" by M. Billinger et al. on page 565.1

ß-blockers are established as standard first-line therapy for both stable and unstable angina pectoris having been introduced to the clinical setting in the mid-1960s. This class of drug is effective in alleviating the symptoms of angina but has never been shown to impact on mortality in patients with chronic stable angina. Several large clinical trials have shown ß-blockers to reduce mortality when used in patients after myocardial infarction and more recently in heart failure.1–3 The recently published COMET trial demonstrated mortality benefit of carvedilol (a nonselective ß-blocker and {alpha}-antagonist) compared to metoprolol tartrate (a selective ß1-blocker) in heart failure.4 Thus over recent years the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Coronary collateral perfusion in patients with coronary artery disease: effect of metoprolol
Michael Billinger, Lorenz Raeber, Christian Seiler, Stephan Windecker, Bernhard Meier, and Otto M. Hess
EHJ 2004 25: 565-570. [Abstract] [FREE Full Text]  

Heart rate reduction during exercise-induced myocardial ischaemia and stunning
Xavier Monnet, Patrice Colin, Bijan Ghaleh, Luc Hittinger, Jean-François Giudicelli, and Alain Berdeaux
EHJ 2004 25: 579-586. [Abstract] [FREE Full Text]